HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
VSTM
Verastem, Inc.
There isn't enough reported data to score VSTM yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
VSTM Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
VSTM's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
VSTM PE Valuation
VSTM has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
VSTM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect VSTM's losses to grow, with revenue growing.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
VSTM has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus VSTM down 151%.
VSTM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$3.90 | +$0.14 |
| Q2 2024 | -$4.05 | +$0.32 |
| Q1 2024 | -$5.11 | -$0.67 |
| Q4 2023 | -$4.81 | -$0.25 |
| Q3 2023 | -$4.04 | +$0.64 |
| Q2 2023 | -$4.37 | +$0.79 |
| Q1 2023 | -$4.44 | +$0.48 |
| Q4 2022 | -$4.56 | +$0.36 |
VSTM is still losing money, but far less than before: $2.00 per share over the past year, against $24.12 at its worst in late 2019.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over VSTM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over VSTM on profitability, with a higher operating margin.
VSTM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24M | +114% |
| Q2 2026 | $40.1M | +1775% |
| Q2 2025 | $2.1M | -79% |
| Q1 2022 | $2.6M | +158% |
| Q4 2021 | $545K | +7.7% |
| Q3 2021 | $2K | -100% |
| Q2 2021 | $500K | -88% |
| Q1 2021 | $1M | -80% |
VSTM's revenue is recovering but still below its 2020 peak: $24M last quarter, up 114% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -313% | +49 points |
| Q2 2026 | -82% | +1966 points |
| Q1 2026 | -240% | N/A |
| Q4 2025 | -237% | N/A |
| Q3 2025 | -362% | N/A |
| Q2 2025 | -2048% | -1865 points |
| Q2 2024 | -183% | N/A |
| Q1 2022 | -654% | +748 points |
VSTM's operating margin was −313% last quarter, up 49 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
VSTM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2024 | -$23.8M | -$7.2M |
| Q1 2024 | -$28.3M | -$8M |
| Q4 2021 | -$9.9M | +$11.8M |
| Q3 2021 | -$10.8M | -124% |
| Q1 2021 | -$19.5M | +$14.5M |
| Q4 2020 | -$21.7M | +$15.5M |
VSTM has burned cash in almost every quarter: −$155M over the past year, against −$89M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over VSTM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
VSTM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.1% | +1.1M shares |
| 1 year | +37% | +27.2M shares |
| 3 years | +505% | +84.5M shares |
| 5 years | +615% | +87.1M shares |
| Available history | +1492% | +94.9M shares |
VSTM has 101M diluted shares, up 37% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
VSTM Net Leverage
VSTM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
VSTM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.0 | Neutral |
| Stochastic | 67.9 | Neutral |
VSTM's weekly RSI is 58 (neutral) and its Stochastic is 68 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
VSTM PE vs Healthcare Sector
VSTM has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
VSTM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.64 | 2.3% below |
| 20 week MA | $7.37 | 15% above |
| 50 week MA | $6.54 | 29% above |
| 100 week MA | $6.76 | 25% above |
| 200 week MA | $6.95 | 21% above |
VSTM has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
VSTM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.8 | $27.6 | +64% |
| 2021 | $27.6 | $27.7 | +0.4% |
| 2022 | $27.7 | $4.08 | -85% |
| 2023 | $4.08 | $8.14 | +100% |
| 2024 | $8.14 | $3.71 | -54% |
| 2025 | $3.71 | $8.06 | +117% |
| 2026 YTD | $8.06 | $8.44 | +4.7% |
VSTM has the edge over HIMS on returns for 2026, with the stronger performance.